CNS Pharmaceuticals Reports Q4 Earnings: CEO John Climaco Discusses Results

CNS Pharmaceuticals held an annual shareholder/analyst call on November 17, 2025. CEO John Climaco and CFO Christopher Downs presented the meeting, which was convened and called to order by Climaco. The meeting had been called pursuant to notice, and proxies were solicited on behalf of the Board of Directors. A quorum was required for the consideration of matters to be voted upon, and stockholders were asked to sign the register and present their proxies.